Milrinone: Drug Class, Indications, Mechanism, and Dosing
Milrinone is a phosphodiesterase-3 (PDE-3) inhibitor with combined inotropic and vasodilatory properties, indicated primarily for short-term intravenous treatment of acute decompensated heart failure with low cardiac output syndrome. 1
Drug Classification
Milrinone belongs to the bipyridine class of phosphodiesterase-3 inhibitors (also called inodilators), distinct from both digitalis glycosides and catecholamines 1. It is classified as an intravenous positive inotropic agent that works to increase the heart's contractility and decrease pulmonary vascular resistance 2.
Mechanism of Action
Milrinone selectively inhibits phosphodiesterase-3 enzyme in cardiac and vascular smooth muscle, preventing the breakdown of cyclic adenosine monophosphate (cAMP). 1 This mechanism produces:
- Positive inotropic effects: Increased intracellular cAMP leads to enhanced calcium availability and contractile force in cardiac muscle
- Vasodilation: cAMP-dependent relaxation of vascular smooth muscle, reducing both systemic and pulmonary vascular resistance
- Lusitropic effects: Improved ventricular relaxation
Critically, milrinone's action is independent of beta-adrenergic receptors, meaning it maintains efficacy even in patients on beta-blockers or with down-regulated beta-receptors 3, 4.
Clinical Indications
Primary Indications (Strongest Evidence):
1. Acute Decompensated Heart Failure with Low Cardiac Output
- Patients with reduced cardiac output and end-organ hypoperfusion despite diuretics and vasodilators 5, 6
- Evidence of low cardiac output syndrome: poor perfusion, decreased urine output, cool extremities 6
- Must have preserved or adequate systemic blood pressure (generally SBP >85-90 mmHg) 4, 7
2. Pediatric Heart Failure and Post-Cardiac Surgery
- Children with decompensated heart failure and low cardiac output with end-organ dysfunction 6
- Prevention and treatment of low cardiac output syndrome after pediatric cardiac surgery 6, 8
3. Right Ventricular Dysfunction with Pulmonary Hypertension
- Particularly effective due to potent pulmonary vasodilatory properties 9, 10
- Reduces pulmonary vascular resistance more effectively than catecholamines 3
4. Cardiogenic Shock
- As part of vasoactive support strategy, particularly when combined with vasopressors if needed 11, 12
- May cause less tachycardia than dobutamine 11
5. Post-Cardiac Arrest Care
- To optimize blood pressure, cardiac output, and systemic perfusion in hemodynamically unstable patients 11
Important Contraindications and Cautions:
- Avoid in hypotension (SBP <85 mmHg) unless combined with vasopressors 4, 7
- Use cautiously in hypovolemia - correct volume status first 5
- Requires adequate renal function for clearance 3, 1
- Monitor for arrhythmias, though generally less arrhythmogenic than catecholamines 13, 6
Dosing Regimen
Standard Adult Dosing 1:
Loading Dose:
- 50 mcg/kg administered slowly over 10 minutes
- May be given undiluted or diluted to 10-20 mL for easier visualization
- Can be omitted in hypotensive patients to avoid excessive vasodilation 4, 1
Maintenance Infusion:
- Standard: 0.5 mcg/kg/min (most common)
- Minimum: 0.375 mcg/kg/min
- Maximum: 0.75 mcg/kg/min
- Administered as continuous IV infusion
- Dilute to 200 mcg/mL concentration using 0.45% NaCl, 0.9% NaCl, or 5% Dextrose 1
Total Daily Dose Range:
- Minimum: 0.59 mg/kg/24 hours
- Standard: 0.77 mg/kg/24 hours
- Maximum: 1.13 mg/kg/24 hours (should not exceed) 1
Renal Dose Adjustment 1:
Milrinone requires significant dose reduction in renal impairment:
| Creatinine Clearance | Infusion Rate |
|---|---|
| 50 mL/min | 0.43 mcg/kg/min |
| 40 mL/min | 0.38 mcg/kg/min |
| 30 mL/min | 0.33 mcg/kg/min |
| 20 mL/min | 0.28 mcg/kg/min |
| 10 mL/min | 0.23 mcg/kg/min |
| 5 mL/min | 0.20 mcg/kg/min |
Pediatric Dosing 6, 8:
- Loading dose: 50 mcg/kg over 10 minutes (often divided into smaller aliquots with blood pressure monitoring)
- Maintenance: 0.5-0.75 mcg/kg/min
- Some practitioners avoid loading dose and use infusion only to minimize hypotension risk 3
Hemodynamic Effects
Milrinone produces predictable hemodynamic changes 1, 14:
- Increases: Cardiac output, stroke volume, cardiac index, left ventricular dP/dt
- Decreases: Systemic vascular resistance, pulmonary vascular resistance, pulmonary capillary wedge pressure, left ventricular filling pressure, right atrial pressure
- Minimal effect: Heart rate (less chronotropic than dobutamine)
- May decrease: Mean arterial pressure (dose-dependent vasodilation)
Monitoring Requirements
Essential monitoring during milrinone therapy 6:
- Continuous cardiac monitoring for arrhythmias (tachyarrhythmias, ventricular ectopy)
- Blood pressure monitoring (arterial line preferred in unstable patients)
- Hemodynamic parameters if pulmonary artery catheter in place
- Renal function and electrolytes (especially potassium)
- Clinical perfusion markers (urine output, lactate, mental status)
Duration and Weaning
- Duration depends on patient responsiveness 1
- Typically used for 48-72 hours in acute settings 5
- Requirement for inotropic support >48 hours necessitates a plan for weaning, transition to mechanical support, or consideration of cardiac transplantation 6
- Long half-life (1-10 hours depending on organ function) means effects persist after discontinuation 3
- Gradual weaning recommended, particularly in patients bridging to transplant or chronic therapy 4
Key Clinical Pearls
Advantages over catecholamines:
- Works independently of beta-receptors (effective with beta-blockers) 3, 4
- Potent pulmonary vasodilator 9
- Less tachycardia and arrhythmias than dobutamine 11
- No tolerance development 15
Critical limitations: